Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2020, XLVIII/284: 120-123 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2020, XLVIII/284: 120-123

Title: An association of selected polymorphisms of the lactoferrin gene and genes for lactoferrin receptors in the prevalence of metabolic disorders in obese subjects 

Authors: Kaczmarek N, Jamka M, Walkowiak J. 

More details

11/284

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

An association of selected polymorphisms of the lactoferrin gene and genes for lactoferrin receptors in the prevalence of metabolic disorders in obese subjects

Kaczmarek N, Jamka M, Walkowiak J.

Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poland

Lactoferrin is a multipotent protein that belongs to the transferrin family. It was first isolated from cow’s milk in 1939. In the 1960s, it was also found in breast milk. In the human body, lactoferrin can also be found in other body fluids, e.g., saliva, tears, and vaginal discharge. Its biological activity depends on receptors present on the membrane surface of many cells, such as neutrophils, hepatocytes, and intestinal epithelial cells. Lactoferrin can bind iron. Because of this property, it also has antibacterial, antiviral, and antifungal activity. Its antiinflammatory and anticancer activity has also been confirmed. Recent studies have demonstrated that lactoferrin might have a beneficial effect in the prevention and treatment of obesity-related metabolic abnormalities, such as type 2 diabetes, hypertension, and dyslipidaemia. It is also worth to notice the potential relationship between polymorphisms in lactoferrin gene, genes for lactoferrin receptors and metabolic abnormalities in obese subjects.

Key words: lactoferrin, metabolic disorders, polymorphism, genetic

Pol Med J, 2020; XLVIII (284); 120–123